Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system

References

• Harazono Y, Kho DH, Balan V, et al. Extracellular galectin-3 programs multidrug resistance throuhg Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget. 2015;6:19592–19604.
   PubMed Web of Science ®Google Scholar
• Pereira AR, Menezes-Falcão L. Galectin-3, a prognostic marker-and a therapeutic target? Rev Port Cardiol. 2015;34:201–208.
   PubMedGoogle Scholar
• Giordano M, Croci DO, Rabinovich GA. Galectins in hematological malignancies. Curr Opin Hematol. 2013;20:327–335.
   PubMed Web of Science ®Google Scholar
• Fei F, Joo EJ, Tarighat SS, et al. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. Oncotarget. 2015;6:11378–11394.
   PubMed Web of Science ®Google Scholar
• López E, Zafra MP, Sastre B, et al. Gene expression profiling in lungs of chronic asthmatic mice treated with galectin-3: downregulation of inflammatory and regulatory genes. Mediators Inflamm. 2011; 2011:823279.
   PubMed Web of Science ®Google Scholar
• Lippert E, Stieber-Gunckel M, Dunger N, et al. Galectin-3 modulates experimental colitis. Digestion. 2015;92:45–53.
   PubMed Web of Science ®Google Scholar
• de-Oliveira FL, Gatto M, Bassi N, et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015;240:1019–1028.
   PubMed Web of Science ®Google Scholar
• Issa SF, Christensen AF, Lottenburger T, et al. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015;82:70–75.
   PubMed Web of Science ®Google Scholar
• de Boer RA, van der Velde AR, Mueller C, et al. Galectin-3: A modifiable risk factor in heart failure. Cardiovasc Drugs Ther. 2014;28:237–246.
   PubMed Web of Science ®Google Scholar
• Wijk SS, Masson S, Milani V, et al. Interaction of galectin-3 concentrations with the treatment effects of β-blockers and RAS blockade in patients with systolic heart failure: a derivation-validation study from TIME-CHF and GISSI-HF. Clin Chem. 2016;62:605–616.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu X, Wang L, et al. Senescent mesenchymal stem cells promote colorectal cancer cells growth via galectin-3 expression. Cell Biosci. 2015;5:21.
   PubMed Web of Science ®Google Scholar
• Nita-Lazar M, Banerjee A, Feng C, et al. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Mol Immunol. 2015;65:1–16.
   PubMed Web of Science ®Google Scholar
• de Oliveira JT, Ribeiro C, Barros R, et al. Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PLoS One. 2015;10:e0134458.
   Google Scholar
• Linden JR, Kunkel D, Laforce-Nesbitt SS, et al. The role of galectin-3 in phagocytosis of Candida albicans and Candida parapsilosis by human neutrophils. Cell Microbiol. 2013;15:1127–1142.
   PubMed Web of Science ®Google Scholar
• Simovic Markovic B, Nikolic A, Gazdic M, et al. Galectin-3 Plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-1β in macrophages. J Crohns Colitis. 2016;10:593–606.
   PubMed Web of Science ®Google Scholar
• Fermin Lee A, Chen HY, Wan L, et al. Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines. Am J Pathol. 2013;183:1209–1222.
   PubMed Web of Science ®Google Scholar
• Yu F, Finley RL, Jr, Raz A, et al. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002;277:15819–15827.
   PubMed Web of Science ®Google Scholar
• Chaudhari AD, Gude RP, Kalraiya RD, et al. Endogenous galectin-3 expression levels modulate immune responses in galectin-3 transgenic mice. Mol Immunol. 2015;68:300–311.
   PubMed Web of Science ®Google Scholar
• Jiang SS, Weng DS, Wang QJ, et al. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014;12:273.
   PubMed Web of Science ®Google Scholar
• Braeuer RR, Zigler M, Kamiya T, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012;72:5757–5766.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin JY, Lee KD, et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 2011;6:e25103.
   Web of Science ®Google Scholar
• Yamaki S, Fujii T, Yajima R, et al. Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today. 2013;43:901–905.
   PubMed Web of Science ®Google Scholar
• Li ZW, Wang Y, Xue WC, et al. Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas. Zhonghua Bing Li Xue Za Zhi. 2013;42:801–805.
   PubMedGoogle Scholar
• Leal MF, Calcagno DQ, Chung J, et al. Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med. 2015;15:415–420.
   PubMed Web of Science ®Google Scholar
• Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 2011;108:17468–17473.
   PubMed Web of Science ®Google Scholar
• Nakayama R, Kuroda J, Taniyama N, et al. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res. 2014;38:103–108.
   PubMed Web of Science ®Google Scholar
• Hoyer KK, Pang M, Gui D, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004;164:893–902.
   PubMed Web of Science ®Google Scholar
• Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood. 2012;120:4635–4644.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee SJ, Sung HJ, et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008;120:211–216.
   PubMed Web of Science ®Google Scholar
• Cheng CL, Hou HA, Lee MC, et al. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood. 2013;121:3172–3180.
   PubMed Web of Science ®Google Scholar
• Asgarian-Omran H, Forghani P, Hojjat-Farsangi M, et al. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocyticleukemia. Cancer Invest. 2010;28:717–725.
   PubMed Web of Science ®Google Scholar
• Liu TY, Chen CY, Tien HF, et al. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology. 2009;54:214–220.
   PubMed Web of Science ®Google Scholar
• D'Haene N, Catteau X, Maris C, et al. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol. 2008;140:402–410.
   PubMed Web of Science ®Google Scholar
• Fei F, Abdel-Azim H, Lim M, et al. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia. 2013;27:2385–2388.
   PubMed Web of Science ®Google Scholar
• Califice S, Castronovo V, Bracke M, et al. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 2004;23:7527–7536.
   PubMed Web of Science ®Google Scholar
• Hu K, Gu Y, Lou L, et al. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway. J Hematol Oncol. 2015; 8:1.
   PubMed Web of Science ®Google Scholar
• Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469–2475.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Löwenberg B, Claudia AJ, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113:3088–3091.
   PubMed Web of Science ®Google Scholar
• Ross SE, Radomska HS, Wu B, et al. Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol. 2004;24:675–686.
   PubMed Web of Science ®Google Scholar
• Baek JH, Kim SJ, Kang HG, et al. Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology. 2015;156:147–156.
   PubMed Web of Science ®Google Scholar
• Gao X, Lin J, Gao L, et al. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia. PLoS One. 2015;10:e0124241.
   Google Scholar
• Gao XN, Yan F, Lin J, et al. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015;29:1730–1740.
   PubMed Web of Science ®Google Scholar
• Xie HM, Gao L, Wang N, et al. FLT3 gene overexpression and its clinical significance in acute myeloid leukemia with AML1/ETO fusion gene positive. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:1199–1205.
   PubMedGoogle Scholar
• Xie HM, Gao L, Wang N, et al. GATA-2 gene overexpression and its clinical significance in acute myeloid leukemia with AML1/ETO fusion gene. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:664–669.
   PubMedGoogle Scholar
• Mirandola L, Yu Y, Chui K, et al. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One. 2011;6:e21811.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gu X, Gong M, et al. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther. 2013;14:897–906.
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Maharaj L, Joel S, et al. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010;115:3939–3948.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65:8350–8358.
   PubMed Web of Science ®Google Scholar